About the Consortium
Uniting Industry Leaders to Revolutionize Fibrosis Treatment
Fibrosis affects multiple organs and remains one of the greatest unmet needs in modern medicine. The FIBRE Consortium (Fibrosis Imaging Biomarker Research & Evaluation) is a first-of-its-kind pre-competitive collaboration designed to address this challenge.
Founded by Perceptive Discovery in partnership with Pfizer, Lantheus, and Lumina Pharmaceuticals, FIBRE aims to accelerate fibrosis drug development by advancing and validating novel imaging biomarkers. Our shared mission is to enable earlier, more accurate detection of fibrotic disease and streamline the path to effective therapies.
Our Research
Focused Innovation in Fibrotic Disease Imaging
Initial research efforts focus on Metabolic Dysfunction-Associated Steatohepatitis (MASH)—a growing global health burden—with plans to expand into additional fibrotic diseases.
Two cutting-edge tracers will be used in our first studies:
- [68Ga]CBP8 targets Collagen Type I, enabling quantification of fibrotic burden
- [18F]LNTH-1363S targets Fibroblast Activation Protein (FAP), a hallmark of fibrotic activity
All imaging studies are conducted at the Perceptive Discovery London Imaging Center, ensuring the highest standards in acquisition, analysis, and regulatory alignment.
Why Imaging Biomarkers?
De-Risk Early Trials. Optimize Development.
Fibrotic diseases are chronic, heterogeneous, and often diagnosed too late. Imaging biomarkers provide:
- Early detection of disease activity
- Quantitative tracking of progression or response
- Smaller, faster, and more cost-effective clinical trials
- Improved decision-making across development phases
Become a Member
Join a Growing Movement to Redefine Fibrosis R&D
FIBRE is a pre-competitive model that welcomes participation from biotech, pharma, and academic institutions. Members gain:
- Leadership opportunities in disease-specific cohort studies
- Access to shared data, imaging protocols, and biomarker analytics
- A role in setting new standards for fibrotic disease evaluation